Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

MRKR – Marker Therapeutics Inc

Marker Therapeutics, Inc.
MRKR
$1.35
Name : Marker Therapeutics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $15,389,055.00
EPSttm : -1.32
finviz dynamic chart for MRKR
Marker Therapeutics, Inc.
$1.35
3.57%
$0.05

Float Short %

1.3

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.14

EPS Last/This Y

EPS This/Next Y

0.51

Price

1.35

Target Price

6

Analyst Recom

1

Performance Q

13.42

Relative Volume

0.2

Beta

1.45

Ticker: MRKR




21 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-07-04MRKR1.6N/AN/A0
2025-07-07MRKR1.562N/AN/A0
2025-07-08MRKR1.6N/AN/A0
2025-07-09MRKR1.82N/AN/A0
2025-07-10MRKR1.81N/AN/A0
2025-07-11MRKR1.705N/AN/A0
2025-07-14MRKR1.57N/AN/A0
2025-07-15MRKR1.57N/AN/A0
2025-07-16MRKR1.6N/AN/A0
2025-07-17MRKR1.925N/AN/A0
2025-07-18MRKR1.67N/AN/A0
2025-07-21MRKR1.54N/AN/A0
2025-07-22MRKR1.618N/AN/A0
2025-07-23MRKR1.58N/AN/A0
2025-07-24MRKR1.51N/AN/A0
2025-07-25MRKR1.56N/AN/A0
2025-07-28MRKR1.5576N/AN/A0
2025-07-29MRKR1.42N/AN/A0
2025-07-30MRKR1.38N/AN/A0
2025-07-31MRKR1.41N/AN/A0
2025-08-01MRKR1.36N/AN/A0
DateSymbolLastP/C OIP/C VolTotal OI
21 items Current Page1 of 1




21 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-07-04MRKR1.60-8.0- -1.19
2025-07-07MRKR1.57-8.0- -1.19
2025-07-08MRKR1.60-8.0- -1.19
2025-07-09MRKR1.81-8.0- -1.19
2025-07-10MRKR1.80-8.0- -1.19
2025-07-11MRKR1.71-8.0- -1.19
2025-07-14MRKR1.58-8.0- -1.19
2025-07-15MRKR1.57-8.0- -1.19
2025-07-16MRKR1.60-8.0- -1.19
2025-07-17MRKR1.92-8.0- -1.19
2025-07-18MRKR1.67-8.0- -1.19
2025-07-21MRKR1.55-8.0- -1.19
2025-07-22MRKR1.60-8.0- -1.19
2025-07-23MRKR1.60-8.0- -1.19
2025-07-24MRKR1.50-8.0- -1.19
2025-07-25MRKR1.56-8.0- -1.19
2025-07-28MRKR1.52-8.0- -1.19
2025-07-29MRKR1.41-8.0- -1.19
2025-07-30MRKR1.38-8.0- -1.19
2025-07-31MRKR1.40-8.0- -1.19
2025-08-01MRKR1.35-8.0- -1.19
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
21 items Current Page1 of 1




21 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-07-04MRKR0.00-13.582.19
2025-07-07MRKR0.00-13.582.19
2025-07-08MRKR0.00-13.582.19
2025-07-09MRKR0.00-13.582.19
2025-07-10MRKR0.00-13.582.19
2025-07-11MRKR0.00-13.581.55
2025-07-14MRKR0.00-13.581.55
2025-07-15MRKR0.00-13.581.55
2025-07-16MRKR0.00-13.581.55
2025-07-17MRKR0.00-13.581.55
2025-07-18MRKR0.00-13.581.55
2025-07-21MRKR0.00-13.581.55
2025-07-22MRKR0.00-13.581.55
2025-07-23MRKR0.00-13.581.55
2025-07-24MRKR0.00-13.581.55
2025-07-25MRKR0.00-13.581.30
2025-07-28MRKR0.00-13.581.30
2025-07-29MRKR0.00-13.581.30
2025-07-30MRKR0.00-13.581.30
2025-07-31MRKR0.00-13.581.30
2025-08-01MRKR0.00-13.581.30
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
21 items Current Page1 of 1

Last Quarter Act. EPS

-0.4

Avg. EPS Est. Current Quarter

-0.27

Avg. EPS Est. Next Quarter

-0.26

Insider Transactions

Institutional Transactions

-13.58

Beta

1.45

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

20

Growth Score

28

Sentiment Score

24

Actual DrawDown %

96.4

Max Drawdown 5-Year %

-98

Target Price

6

P/E

Forward P/E

PEG

P/S

2.68

P/B

1.04

P/Free Cash Flow

EPS

-1.33

Average EPS Est. Cur. Y​

-1.19

EPS Next Y. (Est.)

-0.68

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-224.45

Relative Volume

0.2

Return on Equity vs Sector %

-112

Return on Equity vs Industry %

-93.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Marker Therapeutics, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 5
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia AND myelodysplastic syndromes; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
stock quote shares MRKR – Marker Therapeutics Inc Stock Price stock today
news today MRKR – Marker Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MRKR – Marker Therapeutics Inc yahoo finance google finance
stock history MRKR – Marker Therapeutics Inc invest stock market
stock prices MRKR premarket after hours
ticker MRKR fair value insiders trading